0001755010-25-000003.txt : 20251110
0001755010-25-000003.hdr.sgml : 20251110
20251110155237
ACCESSION NUMBER: 0001755010-25-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering
FILED AS OF DATE: 20251110
DATE AS OF CHANGE: 20251110
EFFECTIVENESS DATE: 20251110
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: EPALEX Corp
CENTRAL INDEX KEY: 0001755010
ORGANIZATION NAME:
EIN: 273424771
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-563583
FILM NUMBER: 251465959
BUSINESS ADDRESS:
STREET 1: 1049 EL MONTE AVENUE, SUITE C 585
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94040
BUSINESS PHONE: 659-946-3366 X700
MAIL ADDRESS:
STREET 1: 1049 EL MONTE AVENUE, SUITE C 585
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94040
D
1
primary_doc.xml
X0708
D
LIVE
0001755010
EPALEX Corp
1049 EL MONTE AVENUE, SUITE C 585
MOUNTAIN VIEW
CA
CALIFORNIA
94040
659-946-3366 X700
DELAWARE
None
None
Corporation
true
Brendan
Magrab
c/o Epalex Corporation
1049 El Monte Avenue, Suite C585
Mountain View
CA
CALIFORNIA
94040
Executive Officer
Director
Didric
Cedarholm
c/o Epalex Corporation
1049 El Monte Avenue, Suite C585
Mountain View
CA
CALIFORNIA
94040
Director
Randall
Murphy
c/o Epalex Corporation
1049 El Monte Avenue, Suite C585
Mountain View
CA
CALIFORNIA
94040
Director
Michael
Rogawski
c/o Epalex Corporation
1049 El Monte Avenue, Suite C585
Mountain View
CA
CALIFORNIA
94040
Director
Jon
Saxe
c/o Epalex Corporation
1049 El Monte Avenue, Suite C585
Mountain View
CA
CALIFORNIA
94040
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2025-10-31
false
true
false
0
3199991
1200000
1999991
false
1
0
0
0
The proceeds are available to fund general working capital requirements; as of the date of this filing, no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of finders fees or other compensation.
false
EPALEX Corp
/s/ Brendan Magrab
Brendan Magrab
Chief Executive Officer
2025-11-09